Por: CNN Health September 28, 2022
CNN — A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. The drug, tested in a Phase 3 global clinical trial, also met all secondary endpoints, showing “target engagement” with reduced amyloid levels – a protein that is one of the hallmarks of Alzheimer’s – and positive effects on cognition... + full article
ABC News USA Business September 29, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared Wednesday after ’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab, reduced... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
How To Spot The Early Signs Of Alzheimer's | Newsweek
Portland Press Herald USA Health September 28, 2022
An experimental Alzheimer’s drug slowed cognitive and functional decline by 27 percent in a closely watched clinical trial, the sponsors of the medication said Tuesday, increasing the therapy’s chance for approval as soon as early next year. Japanese drugmaker Eisai and its... + más
Alzheimer's drug slows progression of cognitive decline in clinical trial, drugmakers say | CNN
New test can detect plaques early in the disease: Alzheimer's Q&A | The Advocate
WPLG Local 10 USA Health September 28, 2022
Shares of Biogen and other drugmakers researching Alzheimer’s disease soared early Wednesday after Japan’s Eisai Co. said its potential treatment appeared to slow the fatal disease in a late-stage study. The drugmaker said early results showed that its treatment, lecanemab,... + más
Associated Press USA Health September 28, 2022
The Advocate USA Health September 26, 2022
Why do people resist enrolling in clinical trials for Alzheimer’s disease?Some of the key challenges that researchers face in conducting studies on Alzheimer’s disease and recruiting candidates include barriers such as lack of time, lack of available diagnostic clinical... + más
Alzheimer's Treatment Shows Promise in Early Results of Study, Drugmaker Says | NBC 6 South Florida
Facebook ad ban may squelch medical research recruitment | Politico
Portland Press Herald USA Health September 24, 2022
A study using the electronic health records of more than 6 million Americans over age 65 found that those who had COVID-19 ran a greater risk of receiving a new diagnosis of Alzheimer’s disease within a year. The study, led by researchers at Case Western Reserve University... + más
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
The Advocate USA Health September 17, 2022
What is the Lumipulse test for Alzheimer’s disease?In May, the U.S. Food and Drug Administration permitted marketing of the Lumipulse (G B-Amyloid Ratio [1-42/1-40]) test to Fujirebio Diagnostics, Inc. of Malvern, Pennsylvania. The test, which was granted Breakthrough Device... + más
Variety of factors play a role in the development of Alzheimer's | The Advocate
Alzheimer's Q&A: Sildenafil has potential as Alzheimer's drug | The Advocate
About iurex | Privacy Policy | Disclaimer |